Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27182
IPSCIO Record ID: 344581
The licensed patents include
— Antibodies and Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Viral Inhibition & Disease Treatment,
— Methods For Treating Viral Infections Using Antibodies To Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Antibodies to Aminophospholipids,
— Methods for Treating Viral Infections Using Immunoconjugates to Aminophospholipids,
— Compositions for Treating Viral Infections Using lmmunoconjugates to Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Immunoconjugates To Aminophospholipids,
— Selected Antibodies and Duramycin Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Treating Viral Infections and Cancer,
— Selected Antibody Compositions For Binding To Aminophospholipids,
— Selected Antibody Compositions and Methods For Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Combined Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Selected Antibody CDRs for Binding To Aminophospholipids,
— Liposomes Coated with Selected Antibodies That Bind to Aminophospholipids,
— Combinations and Kits For Cancer Treatment Using Selected Antibodies to Aminophospholipids,
— Selected Immunoconjugates for Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Immunoconjugates For Binding To Aminophospholipids,
— Selected Antibodies & Duramycin Peptides Binding to Anionic Phospholipids & Aminophospholipids &
Their Use in Treating Viral Infections & Cancer,
— Compositions Comprising Cell-Impermeant Duramycin Derivatives,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptide Derivatives,
— Compositions Comprising Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents, and,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents.
IPSCIO Record ID: 356291
For the Manufacturing Grant to Licensee, Licensor grants a co-exclusive license, including the right to sublicense through multiple tiers, under the Licensor Manufacturing Technology, Licensors interest in the Joint Technology, Licensor Patents and the Licensor Platform Technology, to Manufacture the Product for Development worldwide in the Field and for Commercialization in the Field in the Licensee Territory.
By this agreement, Licensor will have the exclusive commercialization rights in the United States and Canada and Licensee will have the exclusive commercialization rights in the rest of the world.
Compound xx414 means a bispecific polypeptide containing a Prostate Specific Membrane Antigen or PSMA Binding derived from murine antibody 107-1A4 and a CD3 Binding Domain derived from murine antibody CRIS-7 (xx414), and any back-up or follow-on compound comprised of a PSMA Binding Domain with or without other Binding Domains, including both a PSMA Binding Domain and a CD3 Binding Domain or both a PSMA Binding Domain and a Binding Domain other than CD3 Binding Domain; and any modification or derivative of the foregoing (including conjugated or mono/multi-specific forms thereof).
CD3 Antigen means the T cell receptor (TCR) complex or any one or more of the CD3 group of cell surface molecules found on T-cells, including TCRa, TCRb, CD3y, CD3d, and CD3e.
CD3 Binding Domain means a Binding Domain that binds the CD3 Antigen and which has greater binding selectivity for the CD3 Antigen versus other antigens (and, for purposes of this definition, disregarding any residual binding activity).
Product Inventions means all Inventions relating to a PSMA Binding Domain, including Inventions relating to composition of matter, method of use and method of manufacture of the Product.
PSMA Antigen means prostate specific membrane antigen (PSMA), also known as the enzyme glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), or NAAG peptidase.
The patents include
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods,
CD3 Binding Polypeptides, Single Chain Multivalent Binding Proteins with Effector Function, Heterodimer Binding Proteins and Uses Thereof, and, Polypeptides Heterodimers and Uses Thereof.
Field means all fields of use, including therapeutic, palliative, prophylactic, diagnostic and research use, in human and animals.
Licensee has significant experience in the development of pharmaceutical products;
